MHRA considers switching ibuprofen gel
This article was originally published in The Tan Sheet
The Medicines and Healthcare products Regulatory Agency seeks comments on potentially switching Ibuleve Speed Relief Max Strength Gel to full OTC access in the U.K. The topical analgesic currently is available without a prescription from the pharmacist. The drug's maker Diomed Developments Ltd. asked MHRA to switch the 10 percent ibuprofen gel for consumer "convenience." The company makes a similar OTC product with 5 percent ibuprofen, but says the more concentrated product would allow consumers the same therapeutic benefit with smaller volume. The firm also wants the agency to increase the allowable tube size from 2.5 grams to 4 grams. To reduce the risk that consumers familiar with the weaker product would overdose on the more concentrated gel, Diomed would highlight the dose volume on the product packaging. Comments on the switch are due April 28
You may also be interested in...
The Medicines and Healthcare products Regulatory Agency increases from 5 percent to 10 percent the maximum strength of ibuprofen gel available via OTC sale for local symptomatic relief of pain and inflammation. In a July 8 decision on Diomed Developments Ltd.'s April 2010 request, the agency approved increasing the maximum OTC - or general sale - ibuprofen pack size from 2.5 g to 4 g (1"The Tan Sheet" April 5, 2010, In Brief)
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.